Perrigo reports Q3 adjusted EPS 80c, consensus 77c

Reports Q3 revenue $1.04B, consensus $1.1B. President and CEO Patrick Lockwood-Taylor commented, “While OTC consumption was increasingly soft in the third quarter, the Perrigo (PRGO) team delivered strong in-market performance. We gained dollar, unit and volume share in five of seven store brand categories and grew share in our key brands, a clear sign that consumers are choosing Perrigo products at the shelf. This performance, despite a challenging backdrop, reflects the strength of our Three-S plan and our commitment to delivering trusted, accessible health solutions across multiple price points.”